Doetsch Grether has received valuation services
Located in the heart of Basel, Switzerland, Doetsch Grether AG is a medium-sized, family-owned company with traditional values that specializes in the marketing and distribution of products in the pharma, OTC and consumer care segments.
Doetsch Grether’s portfolio consists of its own brands, such as the famous Grether’s Pastilles®, neo-angin® and Sulgan®N, as well as distribution brands that include Magnesium-Diasporal®, Tiger Balm® and Pearl Drops®, which are successfully sold throughout Switzerland.
Oaklins’ team in Switzerland has repeatedly advised Doetsch Grether on valuation topics, contract drafting and the preparation of second opinions in connection with various acquisition projects.
Lukas Grimm
CFO, Doetsch Grether AG
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more